Autopsy report · NCT05425550

Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.

“The study was discontinued due to low recruitment rates. Despite various measures, such as training courses and workshops, recruitment rates could not be improved in the long term.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years 9 months before it stopped.
• 196 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Palleos Healthcare GmbH

Sponsor type

Industry

Conditions

Breast Cancer

Interventions

medidux™ app

Participants

196

Sites

1

Countries

Switzerland

Trials that died the same way

• Obesity Hypoventilation Syndrome Prevalence Study
  “This study was stopped due to low recruitment.” (84% match in meaning)
• The Effect of Ovamax on Oocyte Quality
  “The study was stopped prematurely due to low recruitment rate” (83% match in meaning)
• Comparing Palliative Radiotherapy With or Without Carboplatin
  “The study was stopped due to insufficient recruitment.” (81% match in meaning)
• Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients
  “The study was stopped due to recruitment difficulties” (81% match in meaning)
• Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis (BISCIT)
  “Study was stopped due to insufficient recruitment.” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.